In the present study, the combination of @entity1311 and @entity3003 was applied in the treatment of @entity356 . This cytotoxic combination has been an effective regimen with acceptable @entity137 in @entity43 . We evaluated 47 @entity1 (37 male, 10 female), all with @entity1442 and all having undergone prior chemotherapy treatment. All @entity1 had disease progression or no response to the prior treatment. Forty-four @entity1 had undergone a previous gastrectomy for @entity356 and 3 @entity1 were inoperable at diagnosis. @entity1311 175 mg/m2 was administered as a three-hour infusion, followed by @entity3003 5 AUC infused for 90 min. Thirteen (27.66%) @entity1 showed partial response with a median survival of 10 months; 3 (6.38%) @entity1 showed minor response and 13 @entity1 , stable disease with clinical benefit. The median survival of @entity1 with minor response and disease stability was 6 months. Eighteen (38.29%) @entity1 had disease progression with a median survival of 3 months. It appears that in advanced @entity5 @entity1 , the @entity1311 - @entity3003 combination is an effective second-line treatment, resulting in partial response and disease stability in 61% of @entity1 as well as in a prolongation of median survival.

@entity1311 and @entity3003 in pretreated advanced XXXX : a phase II study.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian, lung and head and neck cancers'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric adenocarcinoma', 'gastric carcinoma']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
